Clinical development of chimeric antigen receptor-T cell therapy for hematological malignancies
Abstract. Cellular therapies have revolutionized the treatment of hematological malignancies since their conception and rapid development. Chimeric antigen receptor (CAR)-T cell therapy is the most widely applied cellular therapy. Since the Food and Drug Administration approved two CD19-CAR-T produc...
Main Authors: | Zhihuan Yang, Ying Wang, Peifang Wei |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer
2023-10-01
|
Series: | Chinese Medical Journal |
Online Access: | http://journals.lww.com/10.1097/CM9.0000000000002549 |
Similar Items
-
Chimeric antigen receptor T (CAR‐T) cells: Novel cell therapy for hematological malignancies
by: Samane Abbasi, et al.
Published: (2023-04-01) -
Chimeric Antigen Receptor T Cell Therapy in Hematology
by: Pınar Ataca, et al.
Published: (2015-11-01) -
Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance
by: Michael M. Boyiadzis, et al.
Published: (2018-12-01) -
The breakthrough and the future: CD20 chimeric antigen receptor T‐cell therapy for hematologic malignancies
by: Elaine Tan Su Yin, et al.
Published: (2022-06-01) -
Chimeric Antigen Receptor-T-Cell Therapy for B-Cell Hematological Malignancies: An Update of the Pivotal Clinical Trial Data
by: Gils Roex, et al.
Published: (2020-02-01)